Method Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry for Angiotensin-II in Human Plasma: Application to Study Interaction Between Atorvastatin & Olmesartan Drug Combination

Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was ex...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of clinical biochemistry Vol. 30; no. 3; pp. 334 - 344
Main Authors Das, Rakesh, Pal, Tapan Kumar
Format Journal Article
LanguageEnglish
Published New Delhi Springer India 01.07.2015
Springer
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0970-1915
0974-0422
DOI10.1007/s12291-014-0457-x

Cover

Abstract Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C 18 (cartridges) liquid–liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 μm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50–800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity.
AbstractList Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C18 (cartridges) liquid-liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 μm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50-800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity.
Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C 18 (cartridges) liquid–liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 μm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50–800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity.
Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C.sub.18 (cartridges) liquid-liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 x 4.6 mm, 5 [mu]m) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50-800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity.
Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C 18 (cartridges) liquid–liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 μm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50–800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity.
Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C18 (cartridges) liquid-liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 μm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50-800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity.
Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C^sub 18^ (cartridges) liquid-liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 [mu]m) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50-800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity.
Audience Academic
Author Pal, Tapan Kumar
Das, Rakesh
Author_xml – sequence: 1
  givenname: Rakesh
  surname: Das
  fullname: Das, Rakesh
  organization: Department of Pharmaceutical Technology, Jadavpur University
– sequence: 2
  givenname: Tapan Kumar
  surname: Pal
  fullname: Pal, Tapan Kumar
  email: tkpal12@gmail.com
  organization: Bioequivalence Study Center, Department of Pharmaceutical Technology, Jadavpur University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26089622$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1u1DAUhSNURH_gAdggS0gIFim24_yxQBqmQEdqVcQUtpbj3GRcJXZqO2XmGXkpPDMtdCpAWTixv3NufO85jPa00RBFzwk-Jhjnbx2htCQxJizGLM3j5aPoAJf5-ovSvc07jklJ0v3o0LkrjBOGGXkS7dMMF2VG6UH08xz8wtToBG6gM0MP2iOha_RddKoWXhmNTIPO1PWoajRdWNMLb1orhsUqvgwg9OhcOIfmA0gfTsHbFWqMRRPdKuNBO6Xj2QwpjU7HXmj0pROuF-_QZBg6JbcVvEFzP9YrNNMerJCbzQ_gfwBoNPHG3gjnA6rRK3TR9eCE9cHqxI4tmpq-Unrj8zR63IjOwbPb9Sj69unj5fQ0Prv4PJtOzmKZYeZjIkidllAVDAhuKCmTVDaszitcZVVasZxKWUGeJlVVQSaTgFUNyzMoiiqnuEyOovdb32Gseqhl6JkVHR-s6oVdcSMU3z3RasFbc8MZy0qc5cHg9a2BNdcjOM975SR0ndBgRsdJwCjJE0oD-vIBemVGq8P1AlUULE0yVvyhWtEBV7oxoa5cm_JJTliYOs3XZY__QoUnTFHJEK1Ghf0dwZsdQWA8LH0rRuf4bP51l31xvym_u3EXtQDkW0Ba45yFhkvlN3MLf6E6TjBfh5pvQ81DqPk61HwZlOSB8s78fxq61bjA6hbsvb79U_QLq3cMdw
CitedBy_id crossref_primary_10_1002_bmc_5318
Cites_doi 10.1126/science.173.3991.64
10.1097/00004872-200106001-00004
10.1161/01.HYP.17.2.131
10.1021/ac9707040
10.1056/NEJM199606203342507
10.1161/01.RES.80.2.219
10.1016/0196-9781(91)90070-6
10.1146/annurev.pa.36.040196.001433
10.1016/0003-2697(88)90521-0
10.1016/0378-4347(94)00564-L
10.1056/NEJM197408292910905
10.1146/annurev.physiol.59.1.395
10.1016/S0022-3565(25)19981-3
10.1016/S0031-6997(25)00446-6
ContentType Journal Article
Copyright Association of Clinical Biochemists of India 2014
COPYRIGHT 2015 Springer
Association of Clinical Biochemists of India 2015
Association of Clinical Biochemists of India 2014
Copyright_xml – notice: Association of Clinical Biochemists of India 2014
– notice: COPYRIGHT 2015 Springer
– notice: Association of Clinical Biochemists of India 2015
– notice: Association of Clinical Biochemists of India 2014
DBID AAYXX
CITATION
NPM
ISR
04Q
04W
3V.
7XB
88A
88I
8AO
8FE
8FH
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M2P
M7P
PHGZM
PHGZT
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1007/s12291-014-0457-x
DatabaseName CrossRef
PubMed
Gale In Context: Science
India Database
India Database: Science & Technology
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Indian Journals
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Indian Journals: Science & Technology
ProQuest One Academic
ProQuest Central (Alumni)
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



PubMed
ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 0974-0422
EndPage 344
ExternalDocumentID PMC4469067
3716036861
A714404277
26089622
10_1007_s12291_014_0457_x
Genre Journal Article
Feature
GroupedDBID ---
-4W
-56
-5G
-BR
-EM
-Y2
-~C
.86
.VR
04Q
04W
06C
06D
0R~
0VY
1N0
2.D
203
29I
29~
2CU
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2WC
2~H
30V
3SX
3V.
4.4
406
408
40D
40E
53G
5GY
5VS
67N
6NX
88A
88I
8AO
8FE
8FH
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABDZT
ABECU
ABFTV
ABHQN
ABJNI
ABJOX
ABKCH
ABLLD
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACGFS
ACGOD
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACSNA
ACZOJ
ADBBV
ADFRT
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADYPR
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFGCZ
AFKRA
AFLOW
AFQWF
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
AOIJS
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BAWUL
BBNVY
BBWZM
BDATZ
BENPR
BGNMA
BHPHI
BPHCQ
C1A
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DIK
DNIVK
DPUIP
DU5
DWQXO
E3Z
EBLON
EBS
EIOEI
EJD
EN4
ESBYG
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRP
FRRFC
FSGXE
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GX1
H13
HCIFZ
HF~
HG6
HH5
HMJXF
HRMNR
HVGLF
HYE
HZ~
IAO
IEA
IHR
IJ-
IKXTQ
INH
ISR
ITC
IWAJR
IXC
IXD
I~X
I~Z
J-C
J0Z
JBSCW
JZLTJ
KOV
KPH
LK8
LLZTM
M0L
M2P
M4Y
M7P
MA-
N2Q
NDZJH
NF0
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OK1
P19
PF0
PQQKQ
PROAC
PT4
PT5
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RNI
ROL
RPM
RPX
RSV
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SBY
SCLPG
SDH
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZN
T13
T16
TR2
TSG
TUC
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W2D
W48
WK6
WK8
XSB
YLTOR
Z45
ZMTXR
ZOVNA
~A9
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
NPM
PQGLB
AEIIB
PMFND
7XB
8FK
PKEHL
PQEST
PQUKI
PRINS
PUEGO
Q9U
7X8
5PM
ID FETCH-LOGICAL-c604t-1a1d59eb84e10f21935cf4d7b0b6b5b472ccbe753bbbe6c34e1bf476e88b72093
IEDL.DBID U2A
ISSN 0970-1915
IngestDate Thu Aug 21 18:00:48 EDT 2025
Fri Sep 05 07:30:44 EDT 2025
Wed Sep 10 13:41:19 EDT 2025
Tue Jun 17 21:32:13 EDT 2025
Tue Jun 10 20:54:58 EDT 2025
Fri Jun 27 04:46:42 EDT 2025
Mon Jul 21 05:50:40 EDT 2025
Tue Jul 01 05:01:37 EDT 2025
Thu Apr 24 22:58:43 EDT 2025
Fri Feb 21 02:35:11 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Angiotensin-II
Atorvastatin
Angiotensin-III
LCMS/MS
Drug interaction
Olmesartan
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c604t-1a1d59eb84e10f21935cf4d7b0b6b5b472ccbe753bbbe6c34e1bf476e88b72093
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://link.springer.com/content/pdf/10.1007/s12291-014-0457-x.pdf
PMID 26089622
PQID 1688453648
PQPubID 54403
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4469067
proquest_miscellaneous_1690217322
proquest_journals_1688453648
gale_infotracmisc_A714404277
gale_infotracacademiconefile_A714404277
gale_incontextgauss_ISR_A714404277
pubmed_primary_26089622
crossref_citationtrail_10_1007_s12291_014_0457_x
crossref_primary_10_1007_s12291_014_0457_x
springer_journals_10_1007_s12291_014_0457_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-07-01
PublicationDateYYYYMMDD 2015-07-01
PublicationDate_xml – month: 07
  year: 2015
  text: 2015-07-01
  day: 01
PublicationDecade 2010
PublicationPlace New Delhi
PublicationPlace_xml – name: New Delhi
– name: India
– name: Dordrecht
PublicationTitle Indian journal of clinical biochemistry
PublicationTitleAbbrev Ind J Clin Biochem
PublicationTitleAlternate Indian J Clin Biochem
PublicationYear 2015
Publisher Springer India
Springer
Springer Nature B.V
Publisher_xml – name: Springer India
– name: Springer
– name: Springer Nature B.V
References Torchio, Lombardi, Visconti, Doyle (CR13) 1995; 666
Tian, Meng, Chen (CR1) 1974; 291
Kohara, Brosnihan, Chappell (CR17) 1997; 17
Wolny, Clozel, Rein (CR18) 1997; 80
CR4
De Silva, Husain, Smeby, Khairallah (CR16) 1998; 174
Goodfriend, Elliott, Catt (CR7) 1996; 334
McMahon, Kelly (CR15) 1998; 70
Chiu, McCall, Price, Wong, Carini, Duncia (CR11) 1990; 252
Matsukawa, Ichikawa (CR9) 1997; 59
Norwood, Branch, Bridget, Marlon (CR5) 2002; 27
Laeis, Püchler, Kirch (CR6) 2001; 19
Griendling, Lassegue, Alexander (CR8) 1999; 36
Ganong (CR2) 1973
Ardaillou (CR10) 1999; 10
Toshiro, Kei, Terukazu, Yutaka (CR14) 1999; 729
Ganten, Minnich, Granger, Hayduk, Brecht, Barbeau (CR3) 1971; 173
Kohara, Tabuchi, Senanayeke (CR19) 1991; 12
Timmermans, Wong, Chiu, Herblin, Benfield, Carini (CR12) 1993; 45
K Kohara (457_CR19) 1991; 12
R Ardaillou (457_CR10) 1999; 10
WF Ganong (457_CR2) 1973
T Matsukawa (457_CR9) 1997; 59
KK Griendling (457_CR8) 1999; 36
AT Chiu (457_CR11) 1990; 252
GP McMahon (457_CR15) 1998; 70
M Toshiro (457_CR14) 1999; 729
D Norwood (457_CR5) 2002; 27
P Laeis (457_CR6) 2001; 19
A Wolny (457_CR18) 1997; 80
B Tian (457_CR1) 1974; 291
457_CR4
PB Timmermans (457_CR12) 1993; 45
TL Goodfriend (457_CR7) 1996; 334
D Ganten (457_CR3) 1971; 173
L Torchio (457_CR13) 1995; 666
PE Silva De (457_CR16) 1998; 174
K Kohara (457_CR17) 1997; 17
10410930 - J Chromatogr B Biomed Sci Appl. 1999 Jun 11;729(1-2):89-95
9892138 - J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S30-9
8725391 - Annu Rev Pharmacol Toxicol. 1996;36:281-306
9231832 - Hypertension. 1997 Jul;30(1 Pt 1):128-33
1666184 - Peptides. 1991 Sep-Oct;12(5):1135-41
9074770 - Annu Rev Physiol. 1997;59:395-412
2851278 - Anal Biochem. 1988 Oct;174(1):80-7
9012744 - Circ Res. 1997 Feb;80(2):219-27
7655615 - J Chromatogr B Biomed Appl. 1995 Apr 7;666(1):169-77
8372104 - Pharmacol Rev. 1993 Jun;45(2):205-51
9450367 - Anal Chem. 1998 Jan 15;70(2):409-14
4325865 - Science. 1971 Jul 2;173(3991):64-5
2313596 - J Pharmacol Exp Ther. 1990 Feb;252(2):711-8
11451211 - J Hypertens Suppl. 2001 Jun;19(1):S21-32
8628362 - N Engl J Med. 1996 Jun 20;334(25):1649-54
1846840 - Hypertension. 1991 Feb;17 (2):131-8
References_xml – volume: 173
  start-page: 64
  issue: 3991
  year: 1971
  end-page: 65
  ident: CR3
  article-title: Angiotensin-forming enzyme in brain tissue
  publication-title: Science
  doi: 10.1126/science.173.3991.64
– volume: 19
  start-page: 21
  issue: 1
  year: 2001
  end-page: 32
  ident: CR6
  article-title: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction
  publication-title: J Hypertens Suppl
  doi: 10.1097/00004872-200106001-00004
– volume: 17
  start-page: 131
  year: 1997
  end-page: 138
  ident: CR17
  article-title: Angiotensin-(1-7): a member of circulating angiotensin peptides
  publication-title: Hypertension
  doi: 10.1161/01.HYP.17.2.131
– volume: 10
  start-page: 30
  year: 1999
  end-page: 39
  ident: CR10
  article-title: Angiotensin II receptors
  publication-title: J Am Soc Nephrol
– volume: 729
  start-page: 89
  issue: 2
  year: 1999
  end-page: 95
  ident: CR14
  article-title: Determination of angiotensin metabolites in human plasma by fluorimetric high-performance liquid chromatography using a heart-cut column-switching technique
  publication-title: J Chromatogr B
– volume: 70
  start-page: 409
  issue: 2
  year: 1998
  end-page: 414
  ident: CR15
  article-title: Determination of aspirin and salicylic acid in human plasma by column-switching liquid chromatography using on-line solid-phase extraction
  publication-title: Anal Chem
  doi: 10.1021/ac9707040
– ident: CR4
– volume: 334
  start-page: 1649
  year: 1996
  end-page: 1654
  ident: CR7
  article-title: Angiotensin receptors and their antagonists
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199606203342507
– volume: 45
  start-page: 205
  year: 1993
  end-page: 251
  ident: CR12
  article-title: Angiotensin II receptors and angiotensin II receptor antagonists
  publication-title: Pharmacol Rev
– volume: 80
  start-page: 219
  year: 1997
  end-page: 227
  ident: CR18
  article-title: Functional and biochemical analysis of angiotensin-II forming pathways in human heart
  publication-title: Circ Res
  doi: 10.1161/01.RES.80.2.219
– start-page: 342
  year: 1973
  end-page: 344
  ident: CR2
  publication-title: Review of medical physiology
– volume: 12
  start-page: 1135
  year: 1991
  end-page: 1141
  ident: CR19
  article-title: Reassessment of plasma angiotensins measurement: effects to protease inhibitors and sample handling procedure
  publication-title: Peptides
  doi: 10.1016/0196-9781(91)90070-6
– volume: 36
  start-page: 281
  year: 1999
  end-page: 306
  ident: CR8
  article-title: Angiotensin receptors and their therapeutic implications
  publication-title: Annu Rev Pharmacol Toxicol.
  doi: 10.1146/annurev.pa.36.040196.001433
– volume: 174
  start-page: 80
  year: 1998
  end-page: 87
  ident: CR16
  article-title: Measurement of Immunoreactive angiotensin peptides in rat tissue: some pitfalls in angiotensin-II analysis
  publication-title: Anal Biochem
  doi: 10.1016/0003-2697(88)90521-0
– volume: 27
  start-page: 611
  issue: 12
  year: 2002
  end-page: 618
  ident: CR5
  article-title: Olmesartan medoxomil for hypertension: a clinical review
  publication-title: Drug Forecast
– volume: 666
  start-page: 169
  issue: 1
  year: 1995
  end-page: 177
  ident: CR13
  article-title: Determination of the polar drug dimiracetam in human plasma and serum by column-switching high-performance liquid chromatography
  publication-title: J Chromatogr B
  doi: 10.1016/0378-4347(94)00564-L
– volume: 252
  start-page: 711
  year: 1990
  end-page: 718
  ident: CR11
  article-title: Nonpeptide angiotensin-II receptor antagonists, VII: cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent
  publication-title: J Pharmacol Exp Ther
– volume: 291
  start-page: 446
  year: 1974
  end-page: 457
  ident: CR1
  article-title: Blood Pressures and Cardiovascular Homeostasis in Mice having reduced or absent Angiotensin-Converting Enzyme gene Function
  publication-title: N Engl J Med
  doi: 10.1056/NEJM197408292910905
– volume: 59
  start-page: 395
  year: 1997
  end-page: 412
  ident: CR9
  article-title: Biological functions of angiotensin and its receptors
  publication-title: Annu Rev Physiol
  doi: 10.1146/annurev.physiol.59.1.395
– volume: 80
  start-page: 219
  year: 1997
  ident: 457_CR18
  publication-title: Circ Res
  doi: 10.1161/01.RES.80.2.219
– ident: 457_CR4
– volume: 59
  start-page: 395
  year: 1997
  ident: 457_CR9
  publication-title: Annu Rev Physiol
  doi: 10.1146/annurev.physiol.59.1.395
– volume: 36
  start-page: 281
  year: 1999
  ident: 457_CR8
  publication-title: Annu Rev Pharmacol Toxicol.
  doi: 10.1146/annurev.pa.36.040196.001433
– volume: 174
  start-page: 80
  year: 1998
  ident: 457_CR16
  publication-title: Anal Biochem
  doi: 10.1016/0003-2697(88)90521-0
– start-page: 342
  volume-title: Review of medical physiology
  year: 1973
  ident: 457_CR2
– volume: 729
  start-page: 89
  issue: 2
  year: 1999
  ident: 457_CR14
  publication-title: J Chromatogr B
– volume: 19
  start-page: 21
  issue: 1
  year: 2001
  ident: 457_CR6
  publication-title: J Hypertens Suppl
  doi: 10.1097/00004872-200106001-00004
– volume: 252
  start-page: 711
  year: 1990
  ident: 457_CR11
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)19981-3
– volume: 17
  start-page: 131
  year: 1997
  ident: 457_CR17
  publication-title: Hypertension
  doi: 10.1161/01.HYP.17.2.131
– volume: 334
  start-page: 1649
  year: 1996
  ident: 457_CR7
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199606203342507
– volume: 10
  start-page: 30
  year: 1999
  ident: 457_CR10
  publication-title: J Am Soc Nephrol
– volume: 27
  start-page: 611
  issue: 12
  year: 2002
  ident: 457_CR5
  publication-title: Drug Forecast
– volume: 173
  start-page: 64
  issue: 3991
  year: 1971
  ident: 457_CR3
  publication-title: Science
  doi: 10.1126/science.173.3991.64
– volume: 291
  start-page: 446
  year: 1974
  ident: 457_CR1
  publication-title: N Engl J Med
  doi: 10.1056/NEJM197408292910905
– volume: 666
  start-page: 169
  issue: 1
  year: 1995
  ident: 457_CR13
  publication-title: J Chromatogr B
  doi: 10.1016/0378-4347(94)00564-L
– volume: 12
  start-page: 1135
  year: 1991
  ident: 457_CR19
  publication-title: Peptides
  doi: 10.1016/0196-9781(91)90070-6
– volume: 45
  start-page: 205
  year: 1993
  ident: 457_CR12
  publication-title: Pharmacol Rev
  doi: 10.1016/S0031-6997(25)00446-6
– volume: 70
  start-page: 409
  issue: 2
  year: 1998
  ident: 457_CR15
  publication-title: Anal Chem
  doi: 10.1021/ac9707040
– reference: 9074770 - Annu Rev Physiol. 1997;59:395-412
– reference: 9012744 - Circ Res. 1997 Feb;80(2):219-27
– reference: 8725391 - Annu Rev Pharmacol Toxicol. 1996;36:281-306
– reference: 2313596 - J Pharmacol Exp Ther. 1990 Feb;252(2):711-8
– reference: 9450367 - Anal Chem. 1998 Jan 15;70(2):409-14
– reference: 9231832 - Hypertension. 1997 Jul;30(1 Pt 1):128-33
– reference: 9892138 - J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S30-9
– reference: 7655615 - J Chromatogr B Biomed Appl. 1995 Apr 7;666(1):169-77
– reference: 10410930 - J Chromatogr B Biomed Sci Appl. 1999 Jun 11;729(1-2):89-95
– reference: 1666184 - Peptides. 1991 Sep-Oct;12(5):1135-41
– reference: 8628362 - N Engl J Med. 1996 Jun 20;334(25):1649-54
– reference: 2851278 - Anal Biochem. 1988 Oct;174(1):80-7
– reference: 4325865 - Science. 1971 Jul 2;173(3991):64-5
– reference: 11451211 - J Hypertens Suppl. 2001 Jun;19(1):S21-32
– reference: 8372104 - Pharmacol Rev. 1993 Jun;45(2):205-51
– reference: 1846840 - Hypertension. 1991 Feb;17 (2):131-8
SSID ssj0034041
Score 2.0041447
Snippet Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human...
Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 334
SubjectTerms Acetonitrile
Antihypertensive drugs
Antilipemic agents
Biochemistry
Biomedical and Life Sciences
Chemistry/Food Science
Chromatography
Drug interactions
Drug therapy, Combination
Formic acid
Hypertension
Life Sciences
Liquid chromatography
Mass spectrometry
Methods
Microbiology
Organic acids
Original
Original Article
Pathology
Plasma
Statins
Studies
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgkxAviG8KAx0IgQSKyIftJLygDjatiI5pbGhvke04oxJLtjZF29_IP8Vd4rRNJfbsixPH5_N9_O6OsddBKkJluPWEIdeN0XjmQmWpa6ohkIIwmpKTx_ty75h_PREnzuE2c7DKTiY2gjqvDPnIPwQySbiIJE8-nV941DWKoquuhcZNtokiOEE-39ze2T847GRxxP2md6Wfxr6Hlono4ppN8lwYEuonICCGiL3L3s20Lp9XLqh18ORaBLW5mHbvsjtOo4RhywL32A1b3me3xi5m_oD9HTdNomEFHgSqzOEnauBtQyWoCvg2uZhPcqBauajDujrW3hG5mM9gjBo2UKf6moob1NMrQFUXhuXppGoA8KU3GsGkhCYiAAeokJ-pjzBcxsahroAQi1fQeCDbZArYbjFiMES7_4-i1Cac4w18pyQJ5Gic6st0fgoostB8b-Z5yI53d44-73muhYNnpM9rL1BBLlKrE24Dv0DpGAlT8DzWvpZaaB6HxmiLJpPW2koTIZkueCxtkug49NPoEdsoq9I-YSDDQkUaRYwVKaoVQgVFnibGz2Vq0kCrAfO77cuMq29ObTZ-Z8vKzLTjGe54RjueXQ7Yu8Uj521xj-uIXxFPZFQ0oyRUzqmaz2bZ6MdhNowpRM7DOB6wt46oqPDlRrkkB1wC1dnqUW71KPFUm_5wx3qZkyqzbHkGBuzlYpieJKRcaas50aRkZqKcHrDHLacu1oa2a5JKGol7PLwgoFrj_ZFy8qupOc7JjSLxs9533L7yWf_7ZU-vX8QzdhvVT9GCn7fYRj2d2-eo4tX6hTvH_wAqnFJ_
  priority: 102
  providerName: ProQuest
Title Method Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry for Angiotensin-II in Human Plasma: Application to Study Interaction Between Atorvastatin & Olmesartan Drug Combination
URI https://link.springer.com/article/10.1007/s12291-014-0457-x
https://www.ncbi.nlm.nih.gov/pubmed/26089622
https://www.proquest.com/docview/1688453648
https://www.proquest.com/docview/1690217322
https://pubmed.ncbi.nlm.nih.gov/PMC4469067
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9NAEF6hVkK8IG4MJRoQAglkyceuD95cSGmAlKo0qH2ydtfrEInakDiI_kb-FDM-kjgCJJ78sOP1sbOzc3wzw9hTNxae1NzYQpPrRivcc5401DVVE0hBaEXJyeOj4HDC352JszaPe9Gh3buQZC2p18lunkcoHZeAEyK0UXHcFWi6026ceEknfn3u1O0qnTh0bDRGRBfK_NMUvcNoWyRvnEnbeMmtoGl9Fh3cYNdbJRKSZtVvsiumuMWujtsw-W32a1z3hYYNRBDIIoPPqHQ3PZSgzOHD7PtylgGVx0W1tS1dbZ-SV_kCxqhUAzWnr6ieQTW_BNRuISmms7LGvBf2aASzAuogAByjDn4hX0GyDodDVQKBFC-hdjo2-ROw38DCIEFT_4ekbCac4xl8pLwIZGKc6s18OQWUUmix1_PcYZOD4enrQ7vt2mDrwOGV7Uo3E7FRETeuk6NA9IXOeRYqRwVKKB56WiuDVpJSygTaRzKV8zAwUaRCz4n9u2ynKAtzn0Hg5dJXKFWMiFGTENLNszjSThbEOnaVtJjTLV-q25Lm1Fnja7ouxkwrnuKKp7Ti6U-LvVjd8q2p5_Ev4ifEEynVySgIiDOVy8UiHX06SZOQouLcC0OLPW-J8hIfrmWb14CfQKW1epR7PUrcyLo_3LFe2gqSReoGUcSFH_DIYo9Xw3QngeMKUy6JJibLEkWzxe41nLr6NjRXozigkbDHwysCKi_eHylmX-oy45w8JwG-1suO2zde62-_7MF_UT9k11ABFQ38eY_tVPOleYRKXqUGbDd5e_5-iNf94dHxyaD2ww3qrf4boS1SRg
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF5VqQS8IG4CBQbEIYEsbGfXBxJCKW2V0CRUbYr6ZrzrdbBE7DQHNH-KP8KfYsZHLom-9XnHjjdz7OzMNzOMvbR8YYeKa0MoCt0oiTpnh5qmpioCKQglqTi523Nap_zLmTjbYn-qWhiCVVY2MTfUUaYoRv7ecjyPi4bDvU-jc4OmRlF2tRqhUYjFoZ7_xivb5GN7D_n7yrYP9vufW0Y5VcBQjsmnhhVakfC19Li2zBgVtiFUzCNXmtKRQnLXVkpq9OKllNpRDSSTMXcd7XnStfPmS2jytzlVtNbY9u5-7-i4sv0NbuazMk3fNQ28CYkqj5oX69k2oYwsAn4I17hYOwk3z4OVA3ETrLmRsc0PwoNb7GbpwUKzELnbbEund9i1bpmjv8v-dvOh1LACR4IwjeAbevzFACfIYugk57MkAurNiz5z2Tfb6FNIewhd9OjhZJQP6Bnq6XgO6FpDMx0kWQ64T412G5IU8gwEHOEFYBh-gOYyFw_TDAghOYc84lkUb8BugUmD5jQb_wqplArf8Rq-UlEGahC-am88GwCaSJkUQdJ77PRKmHuf1dIs1Q8ZOHYcNiSaNC18dGNEaMWR7ykzcnzlWzKsM7NiX6DKfuo01uNnsOwETRwPkOMBcTy4qLO3i0dGRTORy4hfkEwE1KQjJRTQIJxNJkH75DhoupSS57br1tmbkijO8MdVWBZV4Baor9ca5c4aJVoRtb5ciV5QWrFJsNS5Onu-WKYnCZmX6mxGND5da_FcqLMHhaQu9oZ3Zc93aMVdk-EFAfU2X19Jkx95j3NOYRsHP-tdJe0rn_W_v-zR5Zt4xq63-t1O0Gn3Dh-zG-j6igJ4vcNq0_FMP0H3ciqfljoN7PtVm5F_mxeQQg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1tb9MwELbQkCa-IN7pGHAgBBIoWl5sJ-FbYFQrrGOCDe1bZDtOqcSS0aaI_Ub-FHd5aZsKkPjsi5vU5_Od77nnGHvmxcJXhltHGLq6MRr3nK8sdU01BFIQRlNx8vhIHpzy92firO1zOu_Q7l1KsqlpIJamotq7yPK9VeGb7xNixyMQhQgddCKvojX2SNFP_aQzxQF369aVbhy6DgYmoktr_mmK3sG0aZ7XzqdN7ORGArU-l4Y32PXWoYSk0YCb7IotbrHtcZsyv81-jese0bCGDgJVZPAFHfCmnxKUORxOvy-mGRBVLrqwLY21c0I3zOcwRgcbqFF9RdwG1ewS0NOFpJhMyxr_XjijEUwLqBMCcIz--Ll6DckqNQ5VCQRYvIT6ArKppYA3DUQMEgz7fyiqbMI5nsNHqpFAhcap9meLCaDFwui9nucOOx2-O3l74LQdHBwjXV45nvIyEVsdceu5ORrHQJicZ6F2tdRC89A3RluMmLTWVpoAxXTOQ2mjSIe-Gwd32VZRFvY-A-nnKtBoYayI0asQysuzODJuJmMTe1oNmNstX2paenPqsvEtXREz04qnuOIprXj6c8BeLh-5aLg9_iX8lHQiJc6MgkA5E7WYz9PR509pElKGnPthOGAvWqG8xB83qq1xwE8gmq2e5G5PEje16Q93qpe2RmWeejKKuAgkjwbsyXKYniSgXGHLBcnEFGWimR6we42mLr8NQ9coljQS9nR4KUBU4_2RYvq1phzndIsi8bVeddq-9lp_-8t2_kv6Mds-3h-mh6OjDw_YNfRLRYOK3mVb1WxhH6LvV-lH9f7-DQlRVTc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Method+Development+and+Validation+of+Liquid+Chromatography-Tandem+Mass+Spectrometry+for+Angiotensin-II+in+Human+Plasma%3A+Application+to+Study+Interaction+Between+Atorvastatin+%26+Olmesartan+Drug+Combination&rft.jtitle=Indian+journal+of+clinical+biochemistry&rft.au=Das%2C+Rakesh&rft.au=Pal%2C+Tapan+Kumar&rft.date=2015-07-01&rft.issn=0970-1915&rft.eissn=0974-0422&rft.volume=30&rft.issue=3&rft.spage=334&rft.epage=344&rft_id=info:doi/10.1007%2Fs12291-014-0457-x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s12291_014_0457_x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0970-1915&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0970-1915&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0970-1915&client=summon